EARLY TESTING PRECLINICAL DEVELOPMENT CLINICAL TRIALS CONTACT ABOUT IRIS PHARMA EFFICACY & PROOF OF CONCEPT EARLY PHARMACOKINETICS PILOT TOLERANCE & SAFETY TESTING FORMULATION & DELIVERY Formulation & Delivery Optimizing the formulation in early testing is critical for ensuring the successful delivery of the molecule to the target site. During preclinical testing, Iris Pharma helps clients determine the most effective formulation strategy for ensuring the successful delivery of a drug to the target site in the eye. Iris Pharma offers innovative, low-volume, non-GMP (Good Manufacturing Practices) preclinical ocular formulations of test substances, and explores the optimal drug delivery system or method of administration in the eye of animals. Bench Formulation Drug Delivery BENCH FORMULATION GEL, SOLUTION, OPHTHALMIC SUSPENSION Our experts develop the most appropriate formulation of ophthalmic drugs – gel, solution, or ophthalmic suspension – for preclinical studies with respect to pH, comfort, solubility, stability, and tolerability. We can create a completely new formulation or optimize an existing drug’s formulation to improve its bioavailability, increase penetration, and possibly decrease the dose regimen necessary for effectiveness. DRUG DELIVERY ANTERIOR AND POSTERIOR CHAMBERS OF THE EYE Iris Pharma has specialists trained in administering preclinical formulations and implanting devices in targeted anterior or posterior ocular tissues in animal models. Advanced administration techniques include the following: Topical instillation Intravitreal (IVT) injections, which are typically most effective for drug administration to posterior ocular tissues Intraocular device implantations Surgical administration Intrascleral, suprascleral, and iontophoresis administration Subconjunctival, sub-Tenon, retrobulbar, periocular, intracameral, subretinal, intrastromal, and suprachoroidal administration Iris Pharma proposes one or more of these specialized drug administration methods as well as more common drug delivery systems including oral, intravenous, and subcutaneous delivery. KEY FIGURE: 3,500 intravitreal injections performed on rabbits and rodents in 2020 Related topics ANIMAL MODELS FOR EYE DISEASES WHO IS IRIS PHARMA WHY IRIS PHARMA EYE RESEARCH CRO SERVICES Have questions or need help with your ophthalmology development programs ? Ask Our Experts Iris Pharma A leading contract research organization (CRO) dedicated to ophthalmic research, Iris Pharma partners with clients to carry out preclinical research and clinical studies involving all areas of the field, from the ocular surface to the posterior segment of the eye. View More Preclinical development In vivo Pharmacology Studies GLP Ocular Tolerance & Safety GLP Ocular Pharmacokinetics Equipment Early testing Efficacy & Proof of Concept Early Pharmacokinetics Pilot Tolerance & Safety Testing Formulation & Delivery Clinical Trials Clinical Trial Services Ophthalmic Indications Clinical Trial Phases Countries About Iris Pharma Who We Are Services Ocular Expertise Publications News & Media Events Legal notice - Sitemap - Contact us Copyright 2021 - Iris Pharma - ckc-net.com This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit Use of cookies Accept cookiesRefuse cookies